Reuters logo
BRIEF-Mateon Therapeutics terminates FOCUS study in ovarian cancer
2017年9月26日 / 晚上10点22分 / 21 天前

BRIEF-Mateon Therapeutics terminates FOCUS study in ovarian cancer

Sept 26 (Reuters) - Mateon Therapeutics Inc:

* Announces termination of focus study in ovarian cancer and restructuring to prioritize OXi4503 for AML

* Company to reduce headcount, concentrate on OXi4503 for Acute Myeloid Leukemia (AML)​

* Remaining members of senior management team will take 50% salary reductions, effective immediately

* Implementing various cost reduction measures, which includes decrease in co’s workforce of about 60% since beginning of year​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below